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A B S T R A C T
 
Background: Induction therapy followed by high-dose chemotherapy and autologous 
transplantation is the standard treatment for suitable patients with multiple myeloma. 
Objective: The aim of this study was to assess whether induction therapy with thalidomide-
containing regimens was associated with improved results compared to vincristine, 
doxorubicin, and dexamethasone, and whether cyclophosphamide, thalidomide, and 
dexamethasone were associated with better results than thalidomide and dexamethasone.
Methods: The records of 152 patients who underwent autologous transplantation at this 
institution from August of 2004 to January of 2012 were reviewed, selecting those with at 
least partial response to a maximum of eight cycles of induction therapy and sufficient 
follow-up information for analysis. 
Results: This study included 89 patients; 44 were female, with a mean age of 55 years (there was a 
significant trend for increasing age over the years of the study). The median number of induction 
therapy cycles was four, again with a trend of increase over the years. At least a very good partial 
response to induction therapy was achieved more often in the cyclophosphamide, thalidomide, 
and dexamethasone group (61.1%) and in the thalidomide and dexamethasone group (59.2%) 
than in the vincristine, doxorubicin, and dexamethasone group (16.2%). The overall median 
progression-free survival was 34 months, with no statistically significant difference between 
the three groups. The overall median survival was not reached, and there was no significant 
difference between the three groups; the estimated five-year overall survival was 55%.
Conclusion: Although the quality of responses appeared to be better with thalidomide-
containing regimens, these improvements did not translate into improved long-term 
outcomes. Given its track record, cyclophosphamide, thalidomide, and dexamethasone is 
currently considered the preferred regimen for first-line induction therapy in the Brazilian 
public health system.
© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 
All rights reserved. 
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Introduction
The use of induction chemotherapy followed by high-dose 
chemotherapy and autologous transplantation has become 
the standard treatment for suitable patients with multiple 
myeloma, in view of increased response rates and improved 
overall survival (OS) when compared with conventional 
chemotherapy.1-4 In parallel, the use of thalidomide has 
emerged as an interesting option for the treatment of 
relapsed or newly diagnosed multiple myeloma.5-7 Given its 
typically lower hematologic toxicity than with conventional 
chemotherapy regimens and its lack of interference with 
stem-cell mobilization,8 thalidomide was rapidly incorporated 
into induction regimens.9 One of the new combinations 
that has demonstrated superiority to the classic vincristine, 
doxorubicin, and dexamethasone (VAD) regimen is 
thalidomide and dexamethasone (TD).10 Moreover, randomized 
trials that assessed triple thalidomide combinations, such 
as thalidomide, doxorubicin, and dexamethasone (TAD), 
cyclophosphamide, thalidomide, and dexamethasone (CTD), 
and bortezomib, thalidomide, and dexamethasone (VTD), 
have shown significantly improved responses with the triple 
combinations containing thalidomide, in comparison with 
corresponding control groups.11-13
Patient access to novel agents is limited in the Brazilian 
public health system, despite the attempt of this system to 
provide full and comprehensive care to the citizens.14 However, 
thalidomide has been available for patients with multiple 
myeloma through the Brazilian public health system for several 
years, thus becoming a good option for induction therapy prior 
to autologous transplantation in the Santa Casa de São Paulo 
Medical School. The present study aimed to describe results 
with different induction treatments used in patients with 
multiple myeloma undergoing autologous transplantation. 
Methods
Patient selection for analysis
For inclusion in this study, 152 patients with multiple myeloma 
who underwent autologous transplantation at this institution 
from August of 2004 to January of 2012 were retrospectively 
selected based on eligibility criteria for the current analysis. 
The key inclusion criterion was indication for autologous 
transplantation according to institutional guidelines (based 
chiefly on patient performance status and the presence of 
comorbidities). At least a partial response (PR) – according to 
the International Myeloma Working Group (IMWG) criteria 
– to induction regimens was present in all but two patients, 
who were referred for transplantation as this was deemed the 
best therapy for them at the time. The number of treatment 
cycles during the induction phase was three or four, based on 
the contemporary institutional protocol, which changed from 
VAD to TD to CTD over the years. Additional selection criteria 
were the receipt of a maximum of eight cycles of induction 
regimens (VAD, TD, or CTD) before transplantation, and 
enough follow-up information to allow for post-transplantation 
response assessment, as some patients had returned to their 
original institution for post-transplantation care. The protocol 
for the current study was approved by the institutional review 
board, which waived an informed consent from patients given 
the retrospective nature of the analysis.
Induction treatment regimens
Patients were treated with one of three induction regimens 
administered on an outpatient basis: (1) VAD; vincristine, 0.4 
mg/day for four days intravenously (IV), doxorubicin, 9 mg/
m2/day for four days IV, and dexamethasone, 40 mg/day on 
days 1 to 4, 9 to 12, and 17-20 orally; (2) TD; thalidomide, 100 
to 200 mg/day according to tolerance, and dexamethasone 
40 mg/week orally every 28 days continuously; or (3) CTD; 
cyclophosphamide, 50 mg/day orally, thalidomide, 100 to 200 
mg/day according to tolerance, and dexamethasone, 40 mg/
week orally every 28 days continuously. The cyclophosphamide 
schedule was based on the GBRAM 0002 CTD protocol 
(NCT01532856),15 comparing three different combinations 
with thalidomide for patients not eligible for autologous 
transplantation. Patients treated with VAD underwent 
transplantation from August of 2004 to September of 2009; 
those treated with TD, from May of 2007 to June of 2011; and 
those treated with CTD, from February of 2009 to January of 
2012. Mobilization was performed with granulocyte colony-
stimulating factor (G-CSF) alone (15 to 20 µg/kg/day for five 
days) for all patients in the TD and CTD groups, and in ten 
patients in the VAD group. Twenty-nine patients in the VAD 
group were mobilized with cyclophosphamide (4 g/m2) + G-CSF 
(10-15 µg/kg/day); of note, 28 patients in this group came from 
the randomized GBRAM 0001 trial (NCT01296503),16 designed to 
assess the role of thalidomide with or without dexamethasone 
as a maintenance therapy for patients after a single autologous 
transplantation. All patients had infection prophylaxis with 
trimethoprim-sulfamethoxazole (800/160 mg four times a 
week) during induction and after transplantation. Patients 
who received thalidomide during the induction treatment 
were given aspirin (100 mg/day) for prophylaxis of deep vein 
thrombosis, unless contraindicated. 
Response assessment
During induction treatment, patients were examined monthly 
for response using the IMWG criteria, without evaluation of 
the free light chains.17 A further category [minimum response 
(MR)], defined by the European Bone Marrow Transplantation 
(EBMT) criteria, was added in the evaluation of response, which 
is defined as a reduction in the monoclonal component by 
more than 25%, but less than 50%.18 An overall response to 
induction treatment was considered when the response was 
at least a PR by the IMWG criteria or MR by the EBMT criteria. 
Patients were reassessed for response at approximately 
100 days after transplantation. Response improvement was 
considered when the response changed between the end of the 
induction phase and after transplantation from PR to at least 
a very good PR (VGPR), or if VGPR was maintained between 
the two phases. None of the patients analyzed in the current 
study had a failed induction treatment, since all underwent 
transplantation.
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Data collection and statistical analysis
The main objective of this study was to compare the outcomes 
of patients with multiple myeloma according to the three 
induction regimens. A secondary objective was the assessment 
of these outcomes in this institution over the years comprised 
in the study. Patients’ medical records were reviewed in order 
to collect baseline and follow-up variables of interest, including 
gender, age, Durie-Salmon (DS) and International Staging 
System (ISS) stages, paraprotein type, number of cycles of 
induction treatment, response after induction treatment and 
after autologous transplantation, and survival status.
Categorical variables were compared between groups using 
Fisher’s exact or the chi-squared test, as appropriate, while 
continuous variables were analyzed by the Student’s t-test 
in the case of two groups or one-way analysis of variance 
(ANOVA) for comparisons across the three groups. No formal 
statistical comparisons were undertaken between treatment 
groups regarding response rates, given that only responding 
patients were included in the study. However, the response 
category (at least VGPR versus less than VGPR) after induction 
treatment was considered a baseline feature of patients in 
each group, and was thus included in multivariate models of 
time-to-event variables of interest. Such variables were OS, 
defined as the time elapsed between day 1 of transplantation 
and death from any cause, and progression-free survival 
(PFS), defined as the time between day 1 of transplantation 
and relapse or progression of multiple myeloma ascertained 
by any clinical, laboratory, or radiographic method. For both 
OS and PFS, data were censored at the last date of contact 
with a patient who was alive or alive and progression-free, 
respectively. OS and PFS were estimated by the Kaplan-Meier 
method and differences between groups were compared 
using the log-rank test. Kaplan-Meier analyses were also used 
to identify potential predictor variables for OS and PFS. Such 
variables were included in Cox regression models that also 
had treatment group as a covariate. Two-sided p-values were 
considered statistically significant when < 0.05. Statistical 
analysis was performed using MedCalc, version 11.0.0.0 
(MedCalc® - Mariakerke, Belgium).
Results
Baseline patient characteristics
Table 1 presents the main demographic and clinical features 
of the 89 patients included in the study, according to induction 
treatment regimens. Three of these patients had undergone 
one previous autologous transplantation and 86 had only the 
index transplantation analyzed herein. Slightly more patients 
were treated with VAD and TD than with CTD. Overall, nearly 
half of patients were female, and the mean age was 55 years. 
There was no significant difference in gender distribution, but 
there was a significant trend for increasing age among groups, 
possibly reflecting increasing experience with transplantation 
over the years. The presence or absence of a plasmacytoma 
was reported more frequently in the TD and CTD groups, but 
no significant difference was found between the three groups 
when only the cases with such information were compared. 
As expected, the length of follow-up was significantly 
different among groups; conversely, there were no statistically 
significant differences in DS or ISS stages; however, regarding 
DS stage, most patients were in stage III in the three groups. 
The median number of induction cycles per patient was four, 
ranging from one to eight; there was a statistically significant 
progressive increase in the proportion of patients with four 
or more induction cycles over the years of the study (p-value 
= 0.01; chi-squared test for trend). The paraprotein type was 
immunoglobulin (Ig) G in nearly half and IgA in nearly one-
quarter of the patients in the three groups, with no significant 
differences in proportions of other subtypes, including light 











Mean age - years 52 55 58 0.05
Gender - n 0.45
    Male 19 14 12
    Female 20 17 7
DSSa - n 0.46
    I 1 0 0
    II 2 5 2
    III 36 25 17
ISSa - n 0.29
    I 11 6 4
    II 17 9 3
    III 7 6 7
Plasmocytoma - n 0.97
    Yes 5 5 4
    No 19 15 15
Number of cycles - n 0.01
    < 4 21 10 4
    ≥ 4 17 16 15
Median follow up - 
monthsa
32.2 14.2 5.5 < 0.01
VAD: vincristine, doxorubicin and dexamethasone; TD: 
thalidomide and dexamethasone; CTD: cyclophosphamide, 
thalidomide and dexamethasone; DSS: Durie-Salmon staging 
system; ISS: International Staging System. 
a Data were missing for one patient regarding DSS, 19 patients 
regarding ISS (from lack of beta-2-microglobulin levels), six 
patients regarding the number of cycles, and 11 patients regarding 
follow-up.
Table 1 - Baseline patient characteristics according to 
induction regimens.
During the induction phase, at least VGPR was achieved 
more frequently in the CTD (61.1%) and TD (59.2%) groups 
than in the VAD group (16.2%); conversely, other response 
categories were more frequent in the VAD group than with 
the thalidomide-containing regimens. After transplantation, 
patients in the TD group had the higher rates of at least VGPR 
(84.6%) when compared with patients in the CTD (63.1%) and 
the VAD (48.5%) groups. As a result of more frequent responses 
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qualifying as at least VGPR in the thalidomide-containing 
groups, response improvement was more frequent in the 
VAD group.
Long-term outcomes of transplantation
The overall median PFS in the 89 patients was 34 months. As 
shown in Figure 1, there was no significant difference in PFS 
between the three groups. Likewise, there was no association 
between PFS and age (≤ 55 versus > 55 years), the number of 
induction cycles, the achievement of at least a VGPR after 
induction treatment, DS stage, or ISS in univariate Kaplan-
Meier analyses. The presence of plasmacytoma was marginally 
associated with decreased PFS (p-value = 0.08). Since age and 
the number of induction cycles were significantly different 
between groups, these two covariates were included in a Cox 
multivariate analyses for PFS that also included treatment 
groups. Only treatment with TD was marginally (and inversely) 
associated with PFS (p-value = 0.04) in this multivariate analysis.
Discussion
The present study was based on a cohort of patients that 
were treated at a single center in Brazil and had as one of its 
goals the comparison between the effectiveness of induction 
therapy with newer regimens (CTD and TD) and that of classic 
VAD. A direct comparison of response rates with these three 
regimens was not deemed appropriate, given the fact that 
only responding patients were selected for analysis (with the 
exception of two patients who were not at least in PR at the time 
of transplantation). It is noteworthy, however, that the quality 
of responses appeared better with the two oral regimens, since 
at least a VGPR was achieved more frequently in these groups 
than in the VAD group. Conversely, such improved responses 
did not translate into improved long-term outcomes, as shown 
by the PFS and OS analyses. However, the retrospective nature 
of this study and the selection criteria for analysis should be 
considered when comparing long-term outcomes in patients. 
Importantly, the PFS and OS curves in the present study 
resemble those from clinical trials of these same therapeutic 
strategies, considering the fact that only patients responding to 
induction therapy were included in the present analysis.
The use of high-dose chemotherapy followed by autologous 
transplantation remains a standard treatment for eligible 
patients with multiple myeloma. Throughout the years, 
the classic VAD regimen has been replaced by newer, 
more effective regimens for induction prior to autologous 
transplantation, and thalidomide is a component of some of 
these newer strategies. In Brazil, this drug is made available by 
the government, allowing for its widespread use for patients 
with multiple myeloma. It has been demonstrated that the 
TD regimen is superior to VAD with regard to responses 
during the induction phase.10 Conversely, clinical trials that 
have used the CTD regimen as first-line therapy for induction 
prior to transplantation are scant. The first report on the 
The median OS of the 89 patients was not reached, and 
the estimated survival proportion at five years was 55%. 
Figure 2 shows the distribution of OS; there was no significant 
difference between the three groups. There was no association 
between OS and the presence of plasmacytoma, the number 
of induction cycles, the achievement of at least a VGPR after 
induction treatment, or DS stage in univariate Kaplan-Meier 
analyses. However, age was marginally associated with OS, 
with younger patients having a shorter survival time (p-value 
= 0.06). Likewise, there as a marginal association between ISS 
and OS (p-value = 0.05). In a stepwise Cox multivariate analyses 
for OS that included age, the number of induction cycles, ISS, 
and treatment groups as covariates, only the presence of ISS 
stage 3 was associated with OS (p-value = 0.01).
Figure 1 - Progression-free survival according to induction regimens. 
CTD: cyclophosphamide, thalidomide and dexamethasone; TD: 
thalidomide and dexamethasone; VAD: vincristine, doxorubicin 
and dexamethasone. Marks represent censoring.
Figure 2 - Overall survival according to induction regimens. 
CTD: cyclophosphamide, thalidomide and dexamethasone; TD: 
thalidomide and dexamethasone; VAD: vincristine, doxorubicin 
and dexamethasone. Marks represent censoring.
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activity of CTD in this setting was a retrospective study by 
Wu et al., in which CTD was considered to have higher efficacy 
and more rapid responses than the cyclophosphamide, 
vincristine, doxorubicin, and methylprednisolone regimen; 
however, no survival comparisons were made between 
the two induction regimens.19 Morgan et al. conducted a 
randomized study and demonstrated an advantage of CTD 
over the cyclophosphamide, vincristine, doxorubicin, and 
dexamethasone regimen, mainly in terms of better responses 
(complete response [CR] and near CR) in the induction phase, 
as well as after transplantation; this study was notable for the 
large number of patients enrolled (n = 1,110).12
The recent paradigm shift in the treatment of multiple 
myeloma has allowed improvements in response rates and patient 
survival. The successful use of high-dose chemotherapy rescued 
by autologous stem-cell transplantation was followed by the use 
of new systemic agents (immunomodulators and proteasome 
inhibitors) for induction therapy with increased refinement in the 
combinations of these agents and the use of three-drug regimens. 
Many centers around the world have been able to incorporate 
combinations of an immunomodulator and bortezomib in their 
daily practice as induction therapy for patients who are eligible 
for transplantation.13 However, such combinations are not feasible 
in many other places due to their cost. There are no studies in 
Brazil that have assessed first-line induction therapy with two 
or three agents for patients with multiple myeloma, regardless 
of their eligibility for transplantation. The chief importance 
of the present study was the assessment of results between 
transplantation-eligible patients treated with a novel agent, 
thalidomide, in the public health system. Arguably, nearly two-
thirds of Brazilian patients with multiple myeloma are treated 
in the public health system, in which thalidomide is available. 
However, the incorporation of other novel agents in this system 
has so far proved difficult. Therapies that are currently available in 
this system were assessed and the results with the regimen that 
the authors currently find most suitable, namely the combination 
of an immunomodulator, an alkylating agent, and a corticosteroid, 
were described. 
The present study assessed whether first-line induction 
therapy with thalidomide-containing regimens might be 
associated with improved results, when compared with VAD, 
and whether a three-drug regimen (CTD) might be associated 
with improved results, when compared with TD. Despite the 
retrospective nature of this study, the relatively small number 
of patients in each of the three groups, and the selection of 
patients who achieved at least a PR to induction therapy, 
the data suggest that thalidomide-containing combinations 
lead to improved responses, in comparison with VAD. In the 
future, the authors plan to collect additional data, from other 
institutions in Brazil, in order to analyze results in a larger 
dataset and over time. Meanwhile, CTD is considered to be 
the best regimen for first-line induction therapy in the public 
health system.
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